AVITA Medical (RCEL) Stock Overview
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RCEL Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.88 |
| 52 Week High | US$11.39 |
| 52 Week Low | US$3.22 |
| Beta | 2.02 |
| 1 Month Change | 23.35% |
| 3 Month Change | 152.69% |
| 1 Year Change | 116.67% |
| 3 Year Change | -38.10% |
| 5 Year Change | -46.97% |
| Change since IPO | -60.48% |
Recent News & Updates
Narrative Update • Sep 07
RCEL: PermeaDerm Economics And Utilization Trends Will Shape Multiple Sustainability
Analysts have raised their blended price target for AVITA Medical to $11.11 per share from $7.04, citing updated models that reflect recent PermeaDerm-I clinical data, higher projected revenue growth, improved margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research on AVITA Medical has centered on the impact of PermeaDerm-I and RECELL trends on both revenue potential and margins, with multiple firms adjusting price targets and ratings in response to new clinical and financial updates.
Narrative Update • Aug 24
RCEL: New Clinical Evidence And Execution Progress Will Shape Future Repricing Potential
Analysts have lifted their blended price target for AVITA Medical to a range that now centers around $11 per share, up from about $9 previously. They cite fresh PermeaDerm-I trial data, broader RECELL adoption and updated models that reflect revised fair value, discount rate and profitability assumptions.Narrative Update • Aug 10
RCEL: Rich Multiple Will Face Pressure If Utilization Momentum Fades
Analysts have lifted their consolidated price target for AVITA Medical stock from $5.49 to $7.04, citing recent Q2 results that were described as a significant beat with improved guidance, broader RECELL utilization, and stabilizing reimbursement trends. Analyst Commentary Recent Street research on AVITA Medical points to a more constructive tone following the latest Q2 update.Recent updates
Narrative Update • Sep 07
RCEL: PermeaDerm Economics And Utilization Trends Will Shape Multiple Sustainability
Analysts have raised their blended price target for AVITA Medical to $11.11 per share from $7.04, citing updated models that reflect recent PermeaDerm-I clinical data, higher projected revenue growth, improved margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research on AVITA Medical has centered on the impact of PermeaDerm-I and RECELL trends on both revenue potential and margins, with multiple firms adjusting price targets and ratings in response to new clinical and financial updates.Narrative Update • Aug 24
RCEL: New Clinical Evidence And Execution Progress Will Shape Future Repricing Potential
Analysts have lifted their blended price target for AVITA Medical to a range that now centers around $11 per share, up from about $9 previously. They cite fresh PermeaDerm-I trial data, broader RECELL adoption and updated models that reflect revised fair value, discount rate and profitability assumptions.Narrative Update • Aug 10
RCEL: Rich Multiple Will Face Pressure If Utilization Momentum Fades
Analysts have lifted their consolidated price target for AVITA Medical stock from $5.49 to $7.04, citing recent Q2 results that were described as a significant beat with improved guidance, broader RECELL utilization, and stabilizing reimbursement trends. Analyst Commentary Recent Street research on AVITA Medical points to a more constructive tone following the latest Q2 update.
Narrative Update • Jul 27
RCEL: Execution And Cash Strength Will Support Recovery And Multiple Expansion
Analysts have lifted their price targets on AVITA Medical stock from about $6 to $12. They point to continued uptake of RECELL, expectations for steady organic revenue growth with solid margins, and sufficient support for the company’s working capital needs as key factors behind the shift.Narrative Update • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.Narrative Update • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Narrative Update • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Narrative Update • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.Narrative Update • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Narrative Update • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Narrative Update • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Narrative Update • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Narrative Update • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Narrative Update • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Narrative Update • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Narrative Update • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Analysis Article • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Analysis Article • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Narrative Update • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Analysis Article • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Narrative Update • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Analysis Article • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Analysis Article • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
New Narrative • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Analysis Article • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Shareholder Returns
| RCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.8% | -5.3% | -1.0% |
| 1Y | 116.7% | 37.0% | 14.1% |
Return vs Industry: RCEL exceeded the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: RCEL exceeded the US Market which returned 13.1% over the past year.
Price Volatility
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 21.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RCEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RCEL's weekly volatility has increased from 14% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 226 | Cary Vance | avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
AVITA Medical, Inc. Fundamentals Summary
| RCEL fundamental statistics | |
|---|---|
| Market cap | US$305.25m |
| Earnings (TTM) | -US$43.08m |
| Revenue (TTM) | US$75.63m |
4.0x
P/S Ratio-7.1x
P/E RatioIs RCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCEL income statement (TTM) | |
|---|---|
| Revenue | US$75.63m |
| Cost of Revenue | US$13.95m |
| Gross Profit | US$61.68m |
| Other Expenses | US$104.76m |
| Earnings | -US$43.08m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 81.56% |
| Net Profit Margin | -56.96% |
| Debt/Equity Ratio | -167.6% |
How did RCEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 03:15 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVITA Medical, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Brenton Anderson | Bell Potter |
| Lyanne Harrison | BofA Global Research |